In the BioHarmony Drug Report Database
Voxelotor
Oxbryta (voxelotor) is a small molecule pharmaceutical. Voxelotor was first approved as Oxbryta on 2019-11-25. It is used to treat sickle cell anemia in the USA. It is known to target cytochrome P450 2C8, cytochrome P450 3A4, and cytochrome P450 2C9. Oxbryta’s patents are valid until 2037-10-12 (FDA).
Trade Name
|
Oxbryta |
|---|---|
Common Name
|
voxelotor |
ChEMBL ID
|
CHEMBL4101807 |
Indication
|
sickle cell anemia |
Drug Class
|
Image (chem structure or protein)